PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › DB-1303

Drugs in development · updated 30 October 2026

DB-1303: clinical trials and development status

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 DB-1303 is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 12 diseases. The most advanced phase is III.

4Active trials
IIIMost advanced phase
12Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow DB-1303 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Breast neoplasmIII3NCT06265428
Endometrial neoplasmIII2NCT06340568
Bile duct neoplasmI–II1NCT05150691
Biliary tract neoplasmI–II1NCT05150691
CarcinomaI–II1NCT05150691
CholangiocarcinomaI–II1NCT05150691
Gastrointestinal neoplasmI–II1NCT05150691
Liver neoplasmI–II1NCT05150691
MetastasisI–II1NCT05150691
NeoplasmI–II1NCT05150691
Non-small-cell lung carcinomaI–II1NCT05150691
Stomach neoplasmI–II1NCT05150691

Everything on DB-1303

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch